JAN 0 7 2002

TECH CENTER 1600/2900 Atty. Dkt. No. 025098





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Peter B. D rvan

Title:

REGULATION OF HER/2 neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES

Appl. No.:

09/807,355

Filing Date:

04/10/2001

Examiner:

Unassigned

Art Unit:

1646

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below 10-10-200 (Date of Deposit)

INFORMATION DISCLUSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents **Box PATENT APPLICATION** Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.



TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b) before the mailing date of the first Office Action on the merits.

.

Atty. Dkt. N . 025098

JAN 0 7 2002 ECH UNITED ASS

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date ____

FOLEY & LARDNER

Customer Number: 23620

23620

23620

PATENT TRADEMARK OFFICE

Telephone:

(858) 847-6721

Facsimile:

(858) 792-6773

Michael A. Whittaker Attorney for Applicant Registration No. 46,230

Carra DTO 44	140	LLC DEDARTME	NT OF COMMERCE	ATTY DOCKET NO		CEDIAL NO	Page 1	<u>of 5</u>	
	m PTO-1449 U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO. 09/807,355				
MODIFIED) PATENT AND TRADEMARK OF			ADEMAKK OFFICE	OE 025098-2802 APPLICANT		L	00/,355		
- INE(ORMATI	ON DISCLOSURE	CITATION	APPLICANT	Peter B. 1	Dervan			
NPE	TP ENFORMATION DISCLOSURE CITATION			FILING DATE					
CT 1 5 2001	YUse s	everal sheets if neces	ssarv)	04/10/2001 1646					
101 1 2001	121 121			NT DOCUMENTS					
in abo							FILING	DATE	
INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS		F	
	A1	4766142	8-23-98 A	camone et al.	514	422			
	A2	4912199	3-27-90 L	owe et al.	530	331			
	A3	5273991	12-28-93 L	98	514	397			
	A4	5502068	3-26-96 L	own et al	514	397			
-	A5	5578444	11-26-96 E	dwards et al.	435	6			
	A6	5753629	05-19-98 B	eria et al	514	18			
-	A7	5776502	07-07-98 F	oulkes et al.	424	617			
	<u> </u>		FOREIGN PA	TENT DOCUMENTS		<u> </u>			
	REF	DOCUMENT DATE		COUNTRY	CLASS	SUB- CLASS	TRANS		
	0.40	NUMBER WO 92/13091	8-6-92 P	 CT		CEAGG	YES	NO	
	A13	WO 92/13031 WO 93/13739		CT		-	<u></u>		
	A14	WO 93/13/39 WO 94/20463		CT		<u> </u>			
	A15	WO 97/03957		CT					
	A16					<u> </u>		l	
			<u> </u>	Author, Title, Date, P					
	A24	Arcamone, et al., "Synthesis, DNA binding and antiviral activity of distamycin analogues containing different,						erent,	
	, = ,	L		g Design, 1986, Vol. 11	·				
	A25	Arcamone, et al., "	tumor activity of r	of novel distamycline derivatives,					
	725	J.Med.Chem., 1989, Vol. 32, p. 774-778.							
	A26	Beran et al., "Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse"						se"	
	AZU	Clinical Cancer Re	search, 1997, Vol. 3	, p. 2377-2384.		•			
	407	Benz et al., "HER2/Neu and the Ets transcriptionactivator PEA3 are coordinately upregulated in human breast							
	A27	Cancer," Oncogene, 1997, Vol. 15, p. 1513-1525.							
	400	Bosher et al., "The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression							
	A28	in human mammary carcinoma," Proc. Nat. Acad. Sci. USA, 1995, Vol. 92, p. 744-747.							
EXAMINER			DATE CONSIDE	ERED					

communicati n t applicant.

Page 2 of 5 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 025098-2802 09/807,355 APPLICANT INFORMATION DISCLOSURE CITATION Peter B. Dervan FILING DATE **GROUP ART UNIT** (Use several sheets if necessary) 04/10/2001 1646 **U.S. PATENT DOCUMENTS** FILING DATE DOCUMENT SUB-**EXAMINER** DATE NAME **CLASS** REF INITIAL **CLASS** NUMBER APPROPRIATE **A8** 5808087 09-15-98 Matsunaga et al. 548 306.1 5998140 12-07-99 Dervan et al. 435 Α9 6090947 07-18-00 Dervan et al. 548 312.4 A10 6143901 11-07-00 Dervan et al 548 312.4 A11 A12

- 5-6 4	440	110 050407145	WT 05 0014155	<u> </u>	ATTI DOOLET		Loggia	Page 3	<u>of 5</u>
Form PTO-1449		U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO.			
MODIFIED) PATENT AND TRADEMARK OFFICE			CE	025098-2	802 	09/807,355			
					APPLICANT				
INFORMATION DISCLOSURE CITATION				Peter B. Dervan					
					FILING DATE		GROUP ART UNIT		
7 15 18 1	15 🎒 🥳 duse several sheets if necessary)			04/10/2001		1646			
	3		FOREIGN	PAT	ENT DOCUMENTS				
ENT & TRIDEN		DOCUMENT DATE		COLINITOV	CLASS	SUB-	TRANSLATION		
1011	REF	NUMBER	DATE		COUNTRY	CLASS	CLASS	YES	NO
	A17	WO 97/28123	8-7-97	PCT					
	A18	WO 98/04524	2-5-98	PCT					
	A19	WO 98/35702	8-20-98	PCT	-			<u> </u>	
	A20	WO 98/37066	8-27-98	PCT					
	A21	WO 98/37067	8-27-98	PCT	•				
	A22	WO 98/45284	10-15-98	PCT	•				
	A23				- · · · · · · · · · · · · · · · · · · ·				
							,		
 :									
								<u> </u>	
,					•				
	 						1	T	1

,	10			<u>Page 4 of 5</u>			
Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.			
(MODIFIED)		PATENT AND TRADEMARK OFFICE	025098-2802	09/807,355			
INFORMATION DISCLOSURE CITATION			APPLICANT Peter B. Dervan				
			FILING DATE	GROUP ART UNIT			
	(Use se	everal sheets if necessary)	04/10/2001	1646			
16 = 2	\	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pages,	Etc.)			
UCT 1 5 2001	¥1 100	Chang et al., "EXS: a structurally unique Ets overexpressed early during human breast tumorigenesis,"					
·	A29	Oncogene, 1997, Vol. 14, p. 1617-1622.					
ENT & TRUCK		Cho et al., "Cyclic polyamides for recognition in the minor groove of DNA," Proc. Nat. Acad. Sci. USA, 1995,					
	A30 -	Vol. 92, p. 10389-10392.					
		Ciucci et al., "Backbone and benzoyl mustard carrying moiety modifies DNA interactions of distamycin					
	A31	analogues," Nucleic Acids Research, 1996, Vol. 24, No. 2, p. 311-315.					
	•	Cozzi et al., "Novel phenyl Nitrogen mustard and half-mustard derivatives of distamycin A," Bioorganic and					
	A32 -	Medicinal Chemistry Letters, 1997, Vol. 7, No. 23, p. 2985-2990.					
		Dennison et al., "Small-molecule-based strategies for controlling genes expression," Chemistry & Biology,					
	A33	June 1998, vol. 5, No. 6, p. 1-17.					
		Ebbinghaus, "Triplex formation inhibits HER-2/neu transcription in vitro," J.Clin.Invest, 1993, Vol. 92,					
	A34 .	p. 2433-2439.					
	405	Geierstranger et al, "Design of a G-C-Specific DNA Minor Groove-Binding Peptide," Science, 1994, Vol. 266,					
	A35	p. 646-650.					
-	A36 ·	Gottesfeld et al., "Regulation of gene expression by small molecules," Nature, 1997, Vol. 387, p. 202-205.					
	A30 ·						
	A37	Lown et al., "Novel linked antiviral and antitumor agents related to netropsin and distamycin: Synthesis and.					
•	A31	biological evaluation," J.Med.Chem., 1989, Vol. 32, p. 2368-2375.					
	A38 ,	Mrksich et al., "Antiparallel side-by-side dimeric motif for sequence-specific recognition in the minor groove					
	A30	of DNA" Proc.Nat.Acad.Sci.USA, 1992, Vol. 89, p. 7586-7590.					
	A20	Mrksich et al., "Antiparallel side-by-side dimeric motif for sequence-specific recognition in the minor groove					
	A39	of DNA"American Chemical Society, 1993, Vol. 115, p. 2572-2576.					
	440 /	Mrksich et al., "Design of a covaient peptide heterodimer for sequence-specific recognition in the minor groove					
	A40 '	of double-helical DNA," J.of the American Chemical Society, 1994, Vol. 11, p. 3663-3664.					
	A 4.4	Mrkish, et al., "Hairpin Peptide Motif.: A new class of oligopeptides for sequence-specific recognition in the					
	A41	minor groove of double-helical DNA," J. of the Amer.Chem.Society, 1994, Vol. 116, p. 7983-7988.					
	A 40 /	Parks et al., Optimization of the hairpin polyamide design for recognition of the minor groove of DNA,"					
	A42 '	J.Am.Chem.Soc., 1996, Vol. 118, p. 6147-6152.					
	A 40	Pasleau et al., "Expression of the c-erbB2	2 gene in the BT474 human mammery	tumor cell line: measurement			
	A43	of c-erbB2 mRNA half-life," Oncogene, 19	993, Vol. 8, p. 849-854.				

<u> </u>				Page 5 of 5				
Form PTO-1449		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.				
(MODIFIED)		PATENT AND TRADEMARK OFFICE	025098-2802	09/807,355				
INFO	RMATI	ON DISCLOSURE CITATION	APPLICANT Peter B. Dervan					
			FILING DATE GROUP ART UNIT					
	(Use se	everal sheets if necessary)	04/10/2001	1646				
		OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pages, Etc.)					
		Pelton et al., "Structural characterization of a 2:1 distamycin A-d(CGCAAATTGGC) complex by two-						
OCT 1 5 2001)A44	dimensional NMR," Proc. Nat. Acad. Sci. USA, 1989, vol. 86, p. 5723-5727.						
	A45	Scott et al., "Binding of an ETS-related protein within the Dnase I hypersensitive site of the HER2/neu						
TRADENALL		Promotor in human breast cancer cells, " J. of Biological Chemistry, 1994, vol. 269, p. 19848-19858.						
	A 40	Tal et al., "Human HER2 (neu) promoter: Evidence for multiple mechanisms for transcriptional initiation,"						
	A46 ·	Mulecular and Cellular Biology, 1987, Vol. 7, No. 7, p. 2597-2601.						
	A47	Trauger et al., "Extension of sequence specific recognition in the minor groove of DNA by pyrrole-imidazole						
	A47	Polyamides to 9-13 base pairs," J. Am. Chem. Soc., 1996, Vol. 118, p. 6160-6166.						
	A48 -	Trauger, et al., "Recognition of DNA by designed ligands at subnanomolar concentrations," Nature, 1996,						
	740	Vol. 382, No. 8, p. 559-561.						
	A49	Wade et al., "Design of peptides that bind in the minor groove of DNA at 5'-(A,T)G(A,T)C(A,T)-3' sequences by						
		a dimeric side-by-side motif," J. of the Amer. Chem. Soc., 1992, vol. 114, p. 8783-8794.						
	A50 ·	White et al, "Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands,"						
		Nature, 1998, Vol. 391, p. 468-471.						
	A51	White et al., "Effects of the A-T/T-A degeneracy of pyrrole-Imidazole polyamide recognition in the minor groove						
		of DNA," Biochemistry, 1996, Vol. 35, p. 12532-12537.						
	A52 ·	White et al, "On the pairing rules for recognition in the minor groove of DNA by pyrrole-imidazole polyamides,"						
		Chemistry & Biology, 1997, Vol. 4, No. 8, p. 569-578.						
	A53							
	A54							
	A55		· · · · · · · · · · · · · · · · · · ·	•				
	A56		,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, 					
	A57							
	A58							
1			•	l				